Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria:

* Histologically confirmed solid tumor or lymphomas (Accrual for Lymphoma Patients Closed as of 11/27/09)
* Refractory to standard treatment OR no standard treatment that is potentially curative or capable of prolonging life expectancy exists
* Tumor amenable to biopsy (patients accrued at the MTD only)
* No CNS metastases
* Performance status - ECOG 0-2
* At least 12 weeks
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9.0 g/dL
* Bilirubin ≤ 2 times upper limit of normal (ULN)
* AST ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2 times ULN (5 times ULN if due to liver involvement)
* Creatinine ≤ 2 times ULN
* QTc \< 500 msec for men (470 msec for women)
* LVEF \> 40% by echocardiogram
* Ejection fraction normal by echocardiogram (for patients who have received prior anthracycline therapy)
* No cardiac symptoms ≥ grade 2
* No New York Heart Association class III or IV heart failure
* No myocardial infarction within the past year
* No active ischemic heart disease within the past year
* No congenital long QT syndrome
* No left bundle branch block
* No history of uncontrolled dysrhythmias or requiring antiarrhythmic drugs
* No history of cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
* No poorly controlled angina
* No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
* No other significant cardiac disease
* Pulse oximetry at rest and exercise \< 88% (per Medicare guidelines)
* No pulmonary symptoms ≥ grade 2
* No significant pulmonary disease requiring oxygen supplementation or causing a severe limitation in activity
* No symptomatic pulmonary disease requiring medication including any of the following:

  * Dyspnea on or off exertion
  * Paroxysmal nocturnal dyspnea
  * Oxygen requirement and significant pulmonary disease, including chronic obstructive/restrictive pulmonary disease
* No home oxygen use that meets the Medicare criteria
* No history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
* No seizure disorder
* No sensory peripheral neuropathy \> grade 1
* No neuropathic pain of any etiology

  * Patients with residual peripheral neuropathy ≤ grade 1 due to oxaliplatin therapy allowed
* No uncontrolled infection
* No prior serious allergic reaction to eggs
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, or Mayo Clinic Florida for follow up
* More than 4 weeks since prior immunotherapy or biologic therapy
* No concurrent prophylactic colony-stimulating factors
* No concurrent immunotherapy, biologic therapy, or gene therapy
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
* No other concurrent chemotherapy
* Concurrent steroids (at a stable dose for ≥ 4 weeks) for comorbid conditions (e.g., adrenal insufficiency or rheumatoid arthritis) allowed
* More than 4 weeks since prior radiotherapy
* No prior radiotherapy that potentially included the heart in the field (e.g., mantle) or chest
* No prior radiotherapy to \> 25% of bone marrow
* No prior radiopharmaceuticals
* No concurrent radiotherapy
* Recovered from prior therapy
* More than 8 weeks since prior UCN-01
* No concurrent warfarin

  * Low molecular weight heparin allowed
* No concurrent medications that prolong or may prolong QTc interval
* No other concurrent investigational therapy